fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Jaypirca (pirtobrutinib) has accelerated approval from the FDA for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two lines of therapy – Eli Lilly

Written by | 8 Dec 2023

Eli Lilly and Company announced that the FDA approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with chronic lymphocytic leukemia or… read more.

Updated data from the phase 1/II BRUIN trial of Jaypirca in patients with covalent BTK inhibitor pre-treated r/r Mantle Cell Lymphoma continue to demonstrate durable efficacy – Eli Lilly

Written by | 5 Jun 2023

A poster presentation (Abstract #7514) presented at ASCO will highlight efficacy data with a median survival follow-up time of two years for Jaypirca in relapsed or refractory MCL… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.